28 unknown, 20 recruiting, 16 completed, 6 active not recruiting. 48 Phase 2, 25 Phase 1, 7 Phase 3, 4 Not applicable, 3 Early Phase 1.
Follow Peripheral T Cell Lymphoma: new trials by email Literature Review of Peripheral T Cell Lymphoma trials Research Report on Peripheral T Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy golidocitinib, Placebo - Peripheral T Cell Lymphoma | Phase 3 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 68 | 2026-02-15 | 2026-02-24 |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 44 | 2026-02-12 | 2026-10-27 |
| A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. BR101801 - Peripheral T Cell Lymphoma | Phase 2 | Not yet recruiting | Boryung Pharmaceutical Co., Ltd | 44 | 2026-02-01 | 2026-01-28 |
| A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma Cidabenamine, Azacitidine - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 40 | 2026-02-01 | 2026-02-05 |
| T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR Autologous Hematopoietic Stem Cell Transplantation, Observation - Peripheral T Cell Lymphoma | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 160 | 2026-01-20 | 2026-01-20 | |
| Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR) Autologous Hematopoietic Stem Cell Transplantation, Allogenic stem cell transplant (ASCT) - Peripheral T Cell Lymphoma | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 88 | 2025-12-31 | 2025-12-23 | |
| Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma Tazemetostat, Linperlisib, Golidocitinib - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 48 | 2025-10-01 | 2025-10-06 |
| T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR Allogenic stem cell transplant (ASCT), Salvage Therapy - Peripheral T Cell Lymphoma | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 58 | 2025-10-01 | 2026-03-13 | |
| Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 101 | 2025-08-27 | 2025-12-31 |
| Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) Golidocitinib, Golidocitinib plus CHOP - Peripheral T Cell Lymphoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 35 | 2025-07-01 | 2025-06-26 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study Golidocitinib, Cyclophosphamide, Doxorubicin - Peripheral T Cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2025-02-21 | 2026-11-03 |
| Tazemetostat Plus CHOP in 1L T-cell Lymphoma Tazemetostat, Doxorubicin, Vincristine - Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Withdrawn | Eric Jacobsen, MD | 2024-12-24 | 2026-04-01 | |
| Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) linperlisib and SHR2554 - Peripheral T Cell Lymphoma | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 33 | 2024-12-01 | 2024-12-02 |
| A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma Linperlisib - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai YingLi Pharmaceutical Co. Ltd. | 606 | 2024-09-10 | 2024-08-12 |
| Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL allogeneic peripheral blood stem cell transplantation - Peripheral T Cell Lymphoma | Not applicable | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 50 | 2024-07-15 | 2024-08-01 |
| RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. Thiotepa - Peripheral T Cell Lymphoma | Phase 2 | Unknown | Xianmin Song, MD | 50 | 2024-07-15 | 2024-08-01 |
| A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). Chidamide - Peripheral T Cell Lymphoma | Phase 2 | Active not recruiting | The First Hospital of Jilin University | 35 | 2024-06-30 | 2024-08-29 |
| CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma CMOEP - Peripheral T Cell Lymphoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 115 | 2024-06-01 | 2024-05-29 |
| GVM±R in Patients With Relapsed or Refractory Aggressive NHL. GVM±R regimen - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 115 | 2024-01-17 | 2025-05-14 |
Showing 20 of 86. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (86) · Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma, T-Cell (9) · Lymphoma, Large-Cell, Anaplastic (7) · Recurrence (7) · Hodgkin Disease (6) · Immunoblastic Lymphadenopathy (6) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Lymphoma, Extranodal NK-T-Cell (5) · Lymphoma, Follicular (5) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (5) · Lymphoma, T-Cell, Cutaneous (4) · Hematologic Neoplasms (3) · Leukemia (3)
Hemic and Lymphatic Diseases (86) · Immune System Diseases (86) · Immunoproliferative Disorders (86) · Lymphatic Diseases (86) · Lymphoproliferative Disorders (86) · Neoplasms by Histologic Type (86) · Neoplasms (85) · Lymphoma (80) · Lymphoma, Non-Hodgkin (80) · Lymphoma, T-Cell (77) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Disease Attributes (12) · Hematologic Diseases (12) · Leukemia, Lymphoid (10)
Cyclophosphamide (12) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (12) · Prednisone (9) · Vincristine (7) · Doxorubicin (6) · Etoposide (6) · Azacitidine (4) · Brentuximab Vedotin (4) · Cytarabine (3) · Dexamethasone (3) · Nivolumab (3) · fludarabine (3) · romidepsin (3) · 10-propargyl-10-deazaaminopterin (2) · AFM13 (2)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (8) · Ruijin Hospital (6) · Institute of Hematology & Blood Diseases Hospital, China (4) · Affimed GmbH (2) · Boryung Pharmaceutical Co., Ltd (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Henan Cancer Hospital (2) · Peking Union Medical College Hospital (2) · Seagen Inc. (2) · Sun Yat-sen University (2) · The Lymphoma Academic Research Organisation (2) · Washington University School of Medicine (2) · Acrotech Biopharma Inc. (1) · BeiGene (1) · CellCentric Ltd. (1)
China (42) · United States (25) · France (8) · South Korea (5) · Spain (5) · Canada (3) · Germany (3) · Italy (3) · Taiwan (3) · Australia (2) · Poland (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Belgium (1) · Hong Kong (1)
Dehui Zou, Dr. (2) · Aichun Liu (1) · Aijun Liao (1) · Anne Beaven, MD (1) · Bing Xu (1) · Bor-Sheng Ko, PhD (1) · Brad Haverkos, MD (1) · Cecilia Larocca, MD (1) · DH Yang, M.D, Ph.D (1) · DH Yoon, M.D, Ph.D (1) · Daobin Zhou, MD (1) · Dominic Lai, MD (1) · EY Lee, M.D, M.S (1)
PMID 19826128, PMID 21355097, PMID 24359243, PMID 25879747, PMID 25891346, PMID 26377597, PMID 26687958, PMID 28264616, PMID 29038340, PMID 33436023, PMID 34515338, PMID 35175355, PMID 35687761, PMID 37276067, PMID 37946283, PMID 39229263, PMID 40199606, PMID 40289142, PMID 40821900
2017 (1), K12CA167540 (1), P50CA186781 (1), R01CA262613 (1)